Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets recover from day's lows
Fri, 8 Jul 01:30 pm

Indian stock market indices have recovered from the day's lows but are still trading in the red. Metals and Oil and Gas stocks are losing the most while those from Realty and Auto space are trading firm.

The BSE-Sensex is down by 21 points while NSE-Nifty is trading 10 points below yesterday's closing. BSE Midcap is up by 0.2% and BSE Small cap index is trading flat. The rupee is trading at 44.30 to the US dollar.

Auto stocks have been trading in the green led by Hero Honda and Tube Investments. As per a leading financial daily, Ashok Leyland plans to hike prices by 1%-2% very soon. The auto major is concerned over falling sales volumes for commercial vehicles. In the month of June, the commercial vehicles sales declined 4.63% YoY. The management has blamed this on rise in retail interest rates that have adversely impacted the demand of heavy vehicles. However, the management expects July sales volumes to be better on a month on month basis. The company plans to sell 1.07 lakh lakh units by FY-12 wherein domestic sales would stand at 95,000 units. It is in the process of launching commercial vehicles in new export markets to counter the shrinking margins in inflation-ridden domestic landscape. The management is optimistic about maintaining its FY12 margin guidance of 10-11% on expectations of increase in market share. The stock was trading in the green.

Pharma stocks have been trading weak in the last two hours of the trade. As per a leading financial daily, Wockhardt has bagged a tentative permission from USFDA for selling 20mg, 30mg and 60mg delayed release capsules of Duloxetine Hydrochloride, a medication utilized for treating depressive disorder. The overall U.S market for this tablet stands at US$ 3.3 bn. The exclusive rights covering this product are under lawsuit in US courts and it will roll out the medicine once they get resolved. The company plans to sustain its growth in the U.S market through a series of such first-to-market launches. The stock was trading in the red.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets recover from day's lows". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.